German Doctors Underspend In 1995

4 March 1996

Despite the rise in German drug spending in 1995, panel doctors in western Germany appear on their own figures to have underspent their drug spending budgets. Western German panel doctors prescribed drugs worth 24.2 billion Deutschemarks ($16.7 million) last year, according to their sector association, the KBV. This was some 240 million marks below the permitted limit. Spen-ding in the eastern German states rose 8.3% last year, and initial estimates by the pharmacy association suggest that eastern German doctors have overshot budgets.

Spending on drugs in western Germany rose 8.1% last year, assisted by a wave of infections in spring 1995, sending spending up 12.1% in the first half of the year. Second-half drug spending increased by only 4.3%, easing budgetary tensions. The KBV notes that drug spending can be controlled "only with difficulty, because of seasonal peaks of illness."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight